B-cell Lymphoma Clinical Trials in Beijing, Beijing Municipality
17 recruitingBeijing, Beijing Municipality, China
Showing 1–17 of 17 trials
Recruiting
Early Phase 1
A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
Relapsed/Refractory Large B-Cell Lymphoma
Shenzhen Fosun Kairos Biotechnology Co., Ltd.12 enrolled6 locationsNCT07606937
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Mantle Cell LymphomaB-cell Lymphoma
BeOne Medicines300 enrolled152 locationsNCT06742996
Recruiting
Phase 2
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)Primary Central Nervous System Lymphoma (PCNSL)
Beijing Tongren Hospital43 enrolled1 locationNCT07523737
Recruiting
Phase 2
Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Daihong Liu30 enrolled1 locationNCT07489989
Recruiting
Phase 2
CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma
Large B-Cell Lymphoma (LBCL)
Beijing Tongren Hospital100 enrolled1 locationNCT07461831
Recruiting
Phase 2
Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Beijing Tongren Hospital50 enrolled1 locationNCT07371923
Recruiting
Early Phase 1
An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma
R/R Aggressive B-cell Lymphoma
Peking University People's Hospital18 enrolled1 locationNCT07344818
Recruiting
Phase 2
Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia
B-cell Lymphoma Refractory
Daihong Liu10 enrolled1 locationNCT07321301
Recruiting
Phase 2
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Guangzhou Lupeng Pharmaceutical Company LTD.150 enrolled41 locationsNCT07189065
Recruiting
Phase 1
A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
B-cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.200 enrolled3 locationsNCT04993690
Recruiting
Phase 1Phase 2
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.97 enrolled21 locationsNCT07124936
Recruiting
Phase 1Phase 2
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
B-cell Lymphoma
Chinese PLA General Hospital30 enrolled1 locationNCT07009002
Recruiting
Phase 3
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc416 enrolled1 locationNCT06792253
Recruiting
Phase 2
A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
B-cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.80 enrolled30 locationsNCT06566586
Recruiting
Phase 1
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
Advanced Solid TumorsRelapsed/Refractory B-cell Lymphoma
InSilico Medicine Hong Kong Limited60 enrolled2 locationsNCT06445517
Recruiting
Phase 1
Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
Non-Hodgkin LymphomaB-cell Lymphoma
Chongqing Precision Biotech Co., Ltd24 enrolled1 locationNCT06180174
Recruiting
Phase 2
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
Diffuse Large B Cell LymphomaB-cell Acute Lymphoblastic LeukemiaB-cell Lymphoma
Beijing Tongren Hospital100 enrolled1 locationNCT06081478